Mongoose Bio, Inc. is an innovative clinical-stage biopharmaceutical company at the forefront of precision oncology, pioneering first-in-class T cell receptor T cell (TCR-T) therapies. By leveraging our proprietary antigen discovery pipeline and advanced memory T cell reprogramming technology, we achieve unparalleled coverage of both common and rare solid tumors, delivering sustained immunoprotection. We integrate Generative Artificial Intelligence (Gen AI) to enhance our antigen discovery and T cell engineering processes, optimizing therapeutic efficacy and patient outcomes.
The science and extensive intellectual property behind Mongoose Bio were developed by Dr. Cassian Yee, a leading oncologist at the prestigious MD Anderson Cancer Center in Houston, Texas. Mongoose Bio holds an exclusive license from MD Anderson to develop and commercialize the TCR-T technology worldwide.
Mongoose Bio’s mission is to generate active and persistent TCR-T therapeutics by epigenetic reprogramming of autologous central memory T-cells harboring defined TCR’s against empirically validated highly immunogenic tumor targets.
Company Details
- Employees
- 3
- Founded
- -
- Address
- Houston, Texas, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.mongoosebio.com
- Keywords
- Biotechnology Research.
- HQ
- Houston, Texas
Mongoose Bio Inc. Questions
Mongoose Bio Inc.'s website is http://www.mongoosebio.com
Mongoose Bio Inc.'s LinkedIn profile is https://www.linkedin.com/company/mongoose-bio-inc
Mongoose Bio Inc. has
3 employees.
View email and phone details for 3
employees at Mongoose Bio Inc..
Mongoose Bio Inc.'s industry is
Biotechnology Research
Mongoose Bio Inc.'s top competitors are
Papillon Therapeutics,
Cellipont Bioservices,
Nona Biosciences,
Immatics,
Factor Bioscience Inc.,
Ernexa Therapeutics,
Virica Biotech,
Matica Biotechnology, Inc.,
Cellular Origins,
Immusoft.
Mongoose Bio Inc.'s categories are Biotechnology Research
Mongoose Bio Inc.'s founding year is 2023
